On January 14, 2021, vTv Therapeutics LLC ("vTv LLC"), a subsidiary of vTv Therapeutics Inc., reported that it entered into the First Amendment to License Agreement with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. ("Huadong") (the "First Amendment") to amend the License Agreement previously entered into between vTv LLC and Huadong on December 21, 2017 (the "Original Agreement") (Filing, 8-K, vTv Therapeutics, JAN 14, 2021, View Source [SID1234574174]). The First Amendment eliminates vTv LLC’s obligation to sponsor a Phase 2 Multi-Region Clinical Trial and corresponding obligation to contribute up to $3.0 million in support of such trial. The First Amendment also reduces the total potential development and regulatory milestone payments of $25.0 million under the Original Agreement by $3.0 million.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!